(Q51774121)

12 April 2018

title

Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. (English)

1 reference

12 April 2018

1 reference

William M Siders

1

1 reference

12 April 2018

Jacqueline Shields

2

1 reference

12 April 2018

Carrie Garron

3

1 reference

12 April 2018

Yanping Hu

4

1 reference

12 April 2018

Paula Boutin

5

1 reference

12 April 2018

Srinivas Shankara

6

1 reference

12 April 2018

William Weber

7

1 reference

12 April 2018

Bruce Roberts

8

1 reference

12 April 2018

Johanne M Kaplan

9

1 reference

12 April 2018

publication date

1 July 2010

1 reference

12 April 2018

published in

Leukemia & Lymphoma

1 reference

12 April 2018

volume

51

1 reference

12 April 2018

issue

7

1 reference

12 April 2018

page(s)

1293-1304

1 reference

12 April 2018

Characterization of the 4C8 antigen involved in transendothelial migration of CD26(hi) T cells after tight adhesion to human umbilical vein endothelial cell monolayers

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgki

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

Clodronate liposomes: perspectives in research and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

Building better magic bullets--improving unconjugated monoclonal antibody therapy for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003777963

10.3109/10428191003777963

21 January 2018

Identifiers

DOI

1 reference

12 April 2018

1 reference

12 April 2018